Analysts expect Doximity to report Q2 2026 revenue of approximately $151.7 million and EPS of $0.16, with the current stock price of $21.24 sitting below the $27.38 average analyst price target.
The primary focus for investors is the AI monetization timeline and whether high engagement with clinical AI tools will finally drive meaningful top-line growth.
Although physician engagement reached record levels recently, management's prior guidance for minimal AI revenue contribution in fiscal 2027 has pressured the stock. Markets are also monitoring the company's net revenue retention and pharmaceutical marketing spend, which have shown signs of sensitivity to macroeconomic conditions.